{"name":"GV20 Therapeutics","slug":"gv20-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxOZmNkTlhyN0VxcjFoT19LVG9RdEFIY0hZUFY0b1M4VEhETWxLdkE3YzVkSEl6ckNUdnRTZm0tMXM0eVJJNHBSS3ljRE5nTVdYcFhmUWgwU1l6UHBuWFJoQmFVWThUa2FiYlQ2OXVtTG43ekEydXRRZWd0a2JidWdpcGZ1MnRlNE5oS2NSTVVwS3F6M3FnclM4WmZOMDcxWXNWV1hXNGxkVFhva3k2X3BYdHVFWHEzenBnc1pheVl0cl9ETGU5TUFVaXJxc2FsTExCR251RE5LNzBzcF9vdElIak1wd2dxTTlEdzRMUDd5Zjdwb3N4b1RUWkZQVFA1WWRTbktQanBDQlZpNW1KRk8yeg?oc=5","date":"2026-03-17","type":"pipeline","source":"PR Newswire","summary":"GV20 Therapeutics Announces Late-Breaking Oral Presentation of GV20-0251 Translational Findings at the AACR Annual Meeting 2026 - PR Newswire","headline":"GV20 Therapeutics Announces Late-Breaking Oral Presentation of GV20-0251 Translational Findings at the AACR Annual Meeti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9STjQwd3FjZzNvM0xTc21aLThoenhjQXJvUnp2aEc4azhtR0F6OXFjenVMOUxuZ2F3Q29FZEJTeTdUWldvMVVRUnRPOFdPNHdycjd4SC1GbVo4ZjZ4X0YtdE02Y090NjVDODFweXN6ZmRBU0N2c2RiczdQaFNEUQ?oc=5","date":"2025-12-09","type":"pipeline","source":"BioSpace","summary":"Antibody Therapeutics Xchange - Boston 2026 - BioSpace","headline":"Antibody Therapeutics Xchange - Boston 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPcjFscERKc1ZZN0tnTjQwRVNWcm9icGZud1FQNzR3TUpQMWNnRFRRTjN4QkRVQjNBVGlKYWNvUjE2Tnd0dnhLeks3ZlBIbVRPRVhFRHJJbTRqRndNRUt0Q1RXYVlaUWFoLUw2bll6QUhFeHBJcUhxVUEtcTBhZVFXT2VrcThKazRvQ2ZJVy0wLXhHczhvaGVSRVlKM1kzcXJPRENlNVA5eDA2ZVVSMmkyclRpUXh5aWt3aUZ1a3hYdUtkYTlxbWdtRkd0ZUQ4TjkzOWhDYy1nSnJ5TFhMNnFBWm12blpZY2U5M3BFbnZ3U3AxczlHV1JzZlRmbDZVLWF4V2o4Ny1NWWxfcHIyNmtORXFveURtRXQ3UVVkSDBZSQ?oc=5","date":"2025-11-25","type":"deal","source":"PR Newswire","summary":"GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe Pharma Corporation - PR Newswire","headline":"GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNYUpNOGdPcjhmUU9kenlNRDZKVVZsQ0Vaa2Y4VFI2YlNhcWxLR2ZlblRhU3FuZ3A0b3hhSFRRWGlSQUJDcUhhRmQ3ZGJ1NEhjMVlnZkFSV0MtcVh4VDRNNHNkcjREU3pIWXVRQXByeVdkZnMwYjZHSkUwY2tnMlZiemdLMlJ2Mnh4a1FWMHZfUllBc20tbFVySGx3WQ?oc=5","date":"2025-11-25","type":"deal","source":"The Pharma Letter","summary":"GV20 advances ADC partnership with Mitsubishi Tanabe - The Pharma Letter","headline":"GV20 advances ADC partnership with Mitsubishi Tanabe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxOY28wdHlqVi1OdzkyV0RGWTRjbGNZXzNKLXI5ZXJ1Ukxic1kyRlBoaDd0QlVXdzdFU1R5X1cyZTQta09jc2pmdFkxak15SjJreS15QVBsMEJ6a2pTcFFmQTZ6Y1M0bm45ejhwNmNIbmloRkc1cnRiVnhVZW5naVFKWTJrRENrd1EycE56Z3puZnViMXdqaDVZUVZUYkZHMjdrV0RYcVBsLThLWkZsX1g1MjE5VTJJWThXR2k4WkRsc05tNEc1NUZhOExrbnJyWnYtTEltTTZ4eU94NC10Vk9HbFphUVJ0MW5kdnlodDdtSnk3dw?oc=5","date":"2025-06-02","type":"trial","source":"PR Newswire","summary":"GV20 Therapeutics Presents Updated Phase 1 Monotherapy Data on GV20-0251 at the ASCO Annual Meeting 2025 - PR Newswire","headline":"GV20 Therapeutics Presents Updated Phase 1 Monotherapy Data on GV20-0251 at the ASCO Annual Meeting 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPR1NtZlVubWFUcVVRLXl4U1ozOTY1OE5JM0FSYWladG5hLV9GWmpSRkxMeUVQaW9TbXF2aFJWcGFNbEVVT29SUnFGNTdTbGV0WWVXMS1PNjJZem04SjJ2X19jdmYtWFJCSXhKYVlpc1pmSkRwTk02aGFuRkVpM0t2dDhUV1BJQ19qZnlpWUxRMmt4ZDNPYldYV1ZfT1JhdHNPNkpMRnNHZ19PZFFRUXkycGkyVnRMUUNaY0VBVHQybXp5bkZrTDkyeHl2ZFNkdV9oMDhlZTdSVmUzMGs0MW5iYnEtUXhiX0p5ODdrcUJ0Z0ROZ1U5?oc=5","date":"2025-05-23","type":"trial","source":"PR Newswire","summary":"GV20 Therapeutics to Present Updated Phase 1 Monotherapy Data on GV20-0251 at the ASCO Annual Meeting 2025 - PR Newswire","headline":"GV20 Therapeutics to Present Updated Phase 1 Monotherapy Data on GV20-0251 at the ASCO Annual Meeting 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNWnA5WW5uRVYzc3JWNl8wcUY2VEFFbDlxbnoxd3FrY1IzbGtLY2QyRC1VbXB2Smw4X21KdHhONWVJUmdRdXdhQjVpalk4OE83QWhTVTJVNmVxUEVGVVg3eHlEQXlsTFdLaHhyWkF4aTFlZ2NkVE5Sc25PTGJaOHdYV25rYVVRX3hTQkdrNXdmVGNTN3I5S19SOVdZelJXWmxVb2xOMUh2UDRONGFHN2xJLUh6WlVBeWQ2dzd1Nm9HTUNvZFVKcHRtYm5vOHFmNUJkZGRjTE9ndXB1bkZ2RXNUR1lkYlFHdkc4MldXRnZXdXA4ZXpFQ0l2SWZoYmxWZlpKV0ZSaTNvN2xwa2FqbVNyU2YzR2lFVk44N19B?oc=5","date":"2025-03-26","type":"deal","source":"PR Newswire","summary":"GV20 Therapeutics Announces Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation to Develop Novel Antibody-Drug Conjugates - PR Newswire","headline":"GV20 Therapeutics Announces Collaboration Agreement with Mitsubishi Tanabe Pharma Corporation to Develop Novel Antibody-","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOTEdLTmZxR0JmMmJIN1BrU1hzTWVCZTRZdjZkdC1Rai1GbV9LMjktTm5CY1htTzluNXI1MnNwTjZDVFUzMDljU3lYckJHbGFQTjB0bll2Wi04TWdRRlA4Wm42SmZNYmxGWWNSUFJ2Q20zTUNOblh6eUtzNkNHcEN1RlhydWc2U3EySlByTmRGbDJJWWphazNOdjc4QjRDMDdqQjFzd2dQTkJkZU9GUlNZalQ0bjZ6VXJHUjJYSUZwVHo3alYwb0NpZHM5R0tKdFBWVnp2NkhJNXBkZWdKWF83X1VxaWYzemZwNFYzWFlaYURtU3lRNEswUDA5elVFR1RoS2dacE81SUJMX00?oc=5","date":"2024-09-16","type":"trial","source":"PR Newswire","summary":"GV20 Therapeutics Presents Promising Phase 1 Monotherapy Data on Novel Checkpoint Inhibitor GV20-0251 at ESMO Congress 2024 - PR Newswire","headline":"GV20 Therapeutics Presents Promising Phase 1 Monotherapy Data on Novel Checkpoint Inhibitor GV20-0251 at ESMO Congress 2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQY2o1Nks4eUx0RUVGWm5jX2hpQnZyMlI2TGdiX0NrN29oeGNHN1RNU3NiQzk2aUVEWEJjWmpvSERodk90YThpa3F4YUxVbkQzNXJfSHo3dzg0b3F0ZG5xUDlHdU8zWUpISW9FeEEweVBkSVBpWmliVTRZbXViaXVneVRGeFgyTmttOFFTMHh3QjBkMUtaWXpNTHhFXzd5ZTJiUVE?oc=5","date":"2024-04-18","type":"trial","source":"curetoday.com","summary":"Novel IGSF8 Plus Keytruda Evaluated in Phase 1 Trial for Solid Tumors - curetoday.com","headline":"Novel IGSF8 Plus Keytruda Evaluated in Phase 1 Trial for Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-04-18","type":"trial","source":"PR Newswire","summary":"GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA® (pembroliz","headline":"GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Aga","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}